Monoclonal antibody inhibition of proprotein convertase subtilisin-kexin type 9 (PCSK9), which reduces LDL cholesterol by about 60% via reducing LDL receptor degradation, improves clinical outcomes in patients with cardiovascular disease (206). Here, PCSK9 is linked to cardiovascular disorder.